Zanubrutinib Shows Worth Against Standard CLL Drugs
Patients with chronic lymphocytic leukemia could soon be offered a novel treatment option after trial data showed zanubrutinib improves outcomes against standard therapies.
United Kingdom Talha Munir Zanubrutinib Brukinsa Lee Greenberger Renata Walewska British Society For Haematology
Source: medscape.com